@article {1822,
	title = {Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.},
	volume = {121},
	year = {2013},
	note = {Status: MEDLINE; Publishing Model: Journal available in: Print-Electronic Citation processed from: Internet; NLM Journal Code: a8g, 7603509; Other ID: Source: NLM. PMC3538330; Grant Number: 5U01HL069294 (United States NHLBI NIH HHS), HHSH234200637015C (United States PHS HHS), HHSH234200637020C (United States PHS HHS), R01 HL085707 (United States NHLBI NIH HHS), U24-CA76518 (United States NCI NIH HHS)},
	month = {Jan 3},
	pages = {197},
	address = {United States},
	abstract = {Although peripheral blood stem cells (PBSCs) have replaced bone marrow (BM) as the most common unrelated donor progenitor cell product collected, a direct comparison of concurrent PBSC versus BM donation experiences has not been performed. We report a prospective study of 2726 BM and 6768 PBSC donors who underwent collection from 2004 to 2009. Pain and toxicities were assessed at baseline, during G-CSF administration, on the day of collection, within 48 hours of donation, and weekly until full recovery. Peak levels of pain and toxicities did not differ between the 2 donation processes for most donors. Among obese donors, PBSC donors were at increased risk of grade 2 to 4 pain as well as grade 2 to 4 toxicities during the pericollection period. In contrast, BM donors were more likely to experience grade 2 to 4 toxicities at 1 week and pain at 1 week and 1 month after the procedure. BM donors experienced slower recovery, with 3\% still not fully recovered at 24 weeks, whereas 100\% of PBSC donors had recovered. Other factors associated with toxicity included obesity, increasing age, and female sex. In summary, this study provides extensive detail regarding individualized risk patterns of PBSC versus BM donation toxicity, suggesting donor profiles that can be targeted with interventions to minimize toxicity.},
	keywords = {Adolescent, Adult, AIM, IM, Anesthesia / ae [Adverse Effects], Blood Cell Count, Blood Component Removal / ae [Adverse Effects], Blood Donors, Bone Marrow Transplantation, Convalescence, Exanthema / ep [Epidemiology], Exanthema / et [Etiology], Fatigue / ep [Epidemiology], Fatigue / et [Etiology], Female, Fever / ep [Epidemiology], Fever / et [Etiology], Gastrointestinal Diseases / ep [Epidemiology], Gastrointestinal Diseases / et [Etiology], Granulocyte Colony-Stimulating Factor / ae [Adverse Effects], Granulocyte Colony-Stimulating Factor / pd [Pharmacology], Hematopoietic Stem Cell Mobilization / ae [Adverse Effects], Hematopoietic Stem Cell Mobilization / mt [Methods], Hospitalization / sn [Statistics \& Numerical Data], Humans, Male, Middle Aged, Obesity / ep [Epidemiology], Pain / ep [Epidemiology], Pain / et [Etiology], Peripheral Blood Stem Cell Transplantation, Prospective Studies, Recombinant Proteins / ae [Adverse Effects], Recombinant Proteins / pd [Pharmacology], Syncope / ep [Epidemiology], Syncope / et [Etiology], Tissue and Organ Harvesting / ae [Adverse Effects], Tissue and Organ Harvesting / mt [Methods], Tissue Donors, United States, Young Adult},
	issn = {0006-4971},
	doi = {http://dx.doi.org/10.1182/blood-2012-03-417667},
	author = {Pulsipher,M. A. and Chitphakdithai,P. and Logan,B. R. and Shaw,B. E. and Wingard,J. R. and Lazarus,H. M. and Waller,E. K. and Seftel,M. and Stroncek,D. F. and Lopez,A. M. and Maharaj,D. and Hematti,P. and O{\textquoteright}Donnell,P. V. and Loren,A. W. and Leitman,S. F. and Anderlini,P. and Goldstein,S. C. and Levine,J. E. and Navarro,W. H. and Miller,J. P. and Confer,D. L.}
}
